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Abstract Protein aggregation is a major pathological
hallmark of many neurodegenerative disorders including
polyglutamine diseases. Aggregation of the mutated form of
the disease protein ataxin-3 into neuronal nuclear inclusions
is well described in the polyglutamine disorder spinocere-
bellar ataxia type 3 (SCA3 or Machado–Joseph disease),
although these inclusions are not thought to be directly
pathogenic.Neuropilaggregateshavenotyetbeendescribed
in SCA3. We performed a systematicimmunohistochemical
study of serial thick sections through brains of seven clini-
cally diagnosed and genetically conﬁrmed SCA3 patients.
Using antibodies against ataxin-3, p62, ubiquitin, the poly-
glutamine marker 1C2 as well as TDP-43, we analyzed
neuronal localization, composition and distribution of
aggregates within SCA3 brains. The analysis revealed
widespread axonal aggregates in ﬁber tracts known to
undergo neurodegeneration in SCA3. Similar to neuronal
nuclearinclusions,theaxonalaggregateswereubiquitinated
and immunopositive for the proteasome and autophagy
associated shuttle protein p62, indicating involvement of
neuronal protein quality control mechanisms. Rare TDP-43
positive axonal inclusions were also observed. Based on
the correlation between affected ﬁber tracts and degenerat-
ing neuronal nuclei, we hypothesize that these novel
axonal inclusions may be detrimental to axonal transport
mechanisms and thereby contribute to degeneration of nerve
cells in SCA3.
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Introduction
Spinocerebellar ataxia type 3 (SCA3) is an autosomal
dominantly inherited progressive neurodegenerative dis-
ease. It usually begins in adulthood and is associated
with gait, stance, and limb ataxia, dysarthria, dysphagia,
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signs, peripheral neuropathy, as well as aspiration pneu-
monia due to dysphagia [1, 9, 27, 33, 39].
Along with dentatorubral-pallidoluysian atrophy, Hun-
tington’s disease, spinobulbar muscular atrophy and the
spinocerebellar ataxias types 1, 2, 6, 7 and 17, SCA3
belongs to the polyglutamine diseases [21, 25, 27, 40, 45].
These severe neurodegenerative diseases are caused by
expanded and meiotically unstable CAG-repeat sequences
at disease-speciﬁc gene loci encoding elongated polyglu-
tamine sequences in the disease protein [21, 25, 40]. The
SCA3 disease gene, ATXN3, codes for the disease protein
ataxin-3 [20], contains 12–40 CAG-repeats in healthy
individuals and approximately 53? CAG-repeats in
affected SCA3 patients and at-risk carriers [27]. Onset and
severity of SCA3 correlates with the length of the expan-
ded CAG-repeats [11].
Ataxin-3 is widely expressed in neuronal and non-neu-
ronal tissue [3, 29, 48] and tends to aggregate into neuronal
nuclear inclusion bodies (NNIs) in vitro and in vivo when
the polyglutamine sequence is expanded. It is well-known
that these NNIs of the disease protein are ubiquitinated,
contain other proteins, including heat shock proteins
(HSPs) and transcription factors [18, 26, 29, 30, 38, 51], are
frequently observed in brain tissue of SCA3 patients and
are regarded as an important morphological hallmark of
neurodegeneration in animal models [5]. However, the
exact role of NNIs in neuronal cell death that occurs in
SCA3 remains uncertain [24, 52]. Since, however, NNIs
are present in degenerated as well as spared brain regions
in advanced SCA3, NNIs are not thought to be directly
pathogenic in affected nerve cells [35].
We here present the ﬁrst systematical study on neuropil
aggregates in SCA3 and describe their axonal localization,
composition and brain distribution. The ataxin-3 immu-
nopositive axonal inclusions newly described in the
present study are immunopositive for ubiquitin and p62
(Sequestosome-1, SQSTM-1), but immunonegative for
hyperphosphorylated tau and alpha-synuclein.
Patients and methods
Patients and control individuals
In the present investigation, we studied the brains of seven
patients with clinically and genetically diagnosed SCA3 (5
males, 2 females, mean age at death 58.1 ± 13.9 years),
along with the brains from two individuals without medical
histories of neuropsychiatric diseases (Table 1). These two
brains were employed as negative controls for the immu-
nohistochemical analyses.
Informed consent was obtained from all patients, in
accordance with the medical ethical committee of the
University Medical Centre Groningen, the Netherlands,
where the autopsies were performed. The ethical board of
the Faculty of Medicine at the Johann Wolfgang Goethe
University of Frankfurt/Main, Germany, also approved the
examination of the brains.
All of the SCA3 patients suffered from gait, stance and
limb ataxia, dysarthria, dysphagia and a variety of oculo-
motor dysfunctions. Genetical diagnosis was carried out in
all SCA3 patients by genotyping the DNA extracted from
peripheral lymphocytes with polymorphic dinucleotide
repeat sequences that ﬂank the speciﬁc ataxin-3 gene loci
[20, 50]. In the SCA3 patients studied, the length of the
normal CAG-repeats varied from 14 to 27, while the
pathologically expanded CAG-repeats varied from 62 to 81
(Table 1).
Brain tissue preparation
Thebrains ofallSCA3patients andcontrolindividualswere
ﬁxed in a 4% phosphate-buffered, aqueous formaldehyde
Table 1 Information on SCA3
patients and healthy controls
Patient number, age of death
(years), gender (F female,
M male), number of CAG-
repeats in the healthy/diseased
SCA3 allele, age at onset of
initial disease symptoms (years)
and duration of disease (years)
(ND not determined)
Case Age at death
(years)
Gender CAG-repeat
length
Age at disease
onset (years)
Disease duration
(years)
SCA3 patients
1 24 M 23/81 13 11
2 45 M 21/69 25 20
3 52 M 14/69 30 22
4 56 M 25/74 30 26
5 62 F 20/73 35 27
6 80 F 27/65 55 25
7 85 M 21/62 59 26
Control cases
88 7 M N D – –
97 4 F N D – –
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123solution (pH 7.4). Thereafter, tissue blocks from the left
cerebral hemispheres and brainstems were embedded in
polyethylene glycol (PEG 1000, Merck, Darmstadt, Ger-
many) [44] and cut into sets of uninterrupted series of
100 lm-thick frontal sections (cerebral tissue blocks) or
100 lm-thick horizontal sections (brainstem tissue blocks)
[8, 32]. Brainstem tissue blocks from case 7 were also
embedded in parafﬁn and cut into 10 lm thick horizontal
sections.
In each instance, one set of cerebral and brainstem serial
sections was stained with Darrow red for Nissl material and
aldehyde-fuchsin for lipofuscin pigment and used for topo-
graphical orientation and assessment of neurodegeneration
[8].
Immunohistochemistry
For the identiﬁcation and subcellular localization of neuropil
aggregates, we employed the anti-ataxin-3 antibody [29]o n
select 100 lm cerebral and brainstem sections (see Table 2
for a list of the primary antibodies). The primary incubation
lasted 20 h at room temperature. This was followed by incu-
bation with a secondary, biotin conjugated antibody for
90 min at room temperature (1:300). Subsequently, we used
the ABC complex (Vectastain, Vector Laboratories, Burlin-
game, CA, USA) and 3,3-diaminobenzidine-tetra-HCl/H2O2
(DAB, D5637 Sigma, Taufkirchen, Germany) to visualize
positive immunoreactions, resulting in a brown staining.
Double immunostaining procedures were employed to
examine the intraaxonal localization, topographical distri-
bution and composition of neuropil aggregates. Axonal
markers (i.e. the AT270 antibody, directed against the
cytoskeletal protein tau; the anti-neuroﬁlament antibody,
directed against neuron speciﬁc intermediate ﬁlaments [15,
43]) were used to ascertain axonal localization of neuropil
aggregates. Additional monoclonal antibodies were applied
as whole cell markers to identify protein aggregates within
neurites of serotonergic (i.e. PH8, directed against trypto-
phan hydroxylase), as well as dopaminergic or
noradrenergic neurons (i.e. MAB 152, directed against
tyrosine hydroxylase) [4, 17].
Inadditiontothepolyclonalrabbitanti-ataxin-3antibody,
we employed the monoclonal 1H9 anti-ataxin-3 [48], TDP-
43 [47] as well as the 1C2 polyglutamine antibodies as
aggregate markers [49]. The possible association of the
axonal aggregates of SCA3 with the proteasomal shuttle
protein p62, known to contribute to aggregations in human
neurodegenerative diseases, was investigated with an anti-
body directed againstp62 [7, 12,22, 23,41, 42]. Axonal and
whole cell stainings were visualized with SK4700, aggre-
gation markers and the anti-p62 antibody with DAB.
For double immunostaining, we followed the single
staining procedure as described above. After the DAB
staining reaction, the slides were rinsed carefully and
incubated with an additional primary antibody (axonal or
whole cell marker) for 20 h at room temperature, followed
Table 2 Information on the primary antibodies
Detection Clone Host species Dilution Source Goal
Ataxin-3 – Rabbit polyclonal 1:750 Henry Paulson laboratory Aggregate marker
Ataxin-3, epitope E214-L233 1H9 Mouse monoclonal 1:2,500 Chemicon (Millipore),
Billerica, MA, USA
Aggregate marker
Ubiquitin p4d1 Mouse monoclonal 1:750 Cell Signaling Technology,
Danvers, MA, USA
Aggregate marker/marker
for proteasomal activity
P62 Sc-25575 Rabbit polyclonal 1:100 Santa Cruz, Delaware, CA,
USA
Aggregate marker/marker
for proteasomal activity
Polyglutamine stretch 1C2 Mouse monoclonal 1:2,000 Chemicon (Millipore),
Billerica, MA, USA
Aggregate marker
Alpha-synuclein – Sheep polyclonal 1:2,000 W.P Gai laboratory Aggregate marker
Hyperphosphorylated tau AT8 Mouse monoclonal 1:2,000 Innogenics, Ghent, Belgium Aggregate marker
Microtubule-associated protein tau AT270 Mouse monoclonal 1:3,000 Pierce Endogen, Rockford,
IL, USA
Axonal marker
Neuroﬁlament ab 30309 Rabbit polyclonal 1:100 Abcam, Cambridge, UK Axonal marker
Tryptophan hydroxylase PH8 Mouse monoclonal 1:1,000 Chemicon (Millipore),
Billerica, MA, USA
Marker for serotonergic
cells
Tyrosine hydroxylase MAB152 Rabbit polyclonal 1:2,000 Chemicon (Millipore),
Billerica, MA, USA
Marker for dopaminergic
and noradrenergic cells
TDP-43 – Rabbit polyclonal 1:1,000 Georg Auburger laboratory Aggregate marker
Antigen detected by antibody, clone or catalog designation (omitted with donated antibodies), host species and clone type, working dilution for
the antibody, source of the antibody, speciﬁc goal of the antibody usage
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123by incubation with a secondary antibody at room temper-
ature for 90 min. This second staining reaction was then
visualized with the SK 4700 Kit (Linaris, 97877 Wertheim,
Germany), resulting in a blue-gray staining.
Double immunoﬂuorescent staining was applied to
ascertain 1C2 and TDP-43 positivity of axonal aggregates,
and to investigate the colocalization of ataxin-3 aggregates
with components of the protein quality control and degra-
dation pathways, or with the disease proteins of human
tauopathies and synucleinopathies. For this, sections were
treated for 10 min with 0.06% sudan-black for quenching
of autoﬂuorescence. Subsequently, the sections were
incubated with both the monoclonal mouse and polyclonal
rabbit primary antibodies for 20 h at room temperature,
followed by secondary incubation for 90 min with Alexa
488, Alexa 568 or Alexa 594 conjugated secondary anti-
bodies (1:1,000, Invitrogen, Carlsbad, CA, USA). Both the
primary and the secondary antibodies were applied simul-
taneously. We used the 1C2 antibody to conﬁrm the
presence of proteins with an expanded polyglutamine
sequence in the axonal aggregates [49]. Ubiquitin [10] and
p62 antibodies were employed to investigate a possible
colocalization of axonal ataxin-3 aggregates with compo-
nents of the protein quality control and degradation
pathways. The anti-tau AT8 antibody and an anti-alpha-
synuclein antibody [6, 14] were used to examine the
association of axonal ataxin-3 aggregates with the hyper-
phosphorylated tau or alpha-synuclein proteins.
Several of the listed antibodies required pre-treatment
for antigen retrieval. To unmask hidden epitopes when
using the 1H9 antibody, sections were autoclaved in
10 mM citrate buffer (pH 6.0) for 20 min. For the anti-
neuroﬁlament and anti-p62 antibodies we employed
10 mM citrate buffer (pH 6.0) at 90C for 30 min. For the
anti-alpha-synuclein antibody we used 100% formic acid at
room temperature. For the 1C2/neuroﬁlament double
immunostaining we employed 3 9 10 min microwaving in
tris Buffer (pH 9.0), followed by 3 min treatment in 99%
formic acid at room temperature. The speciﬁcity of the
immunolabeling was veriﬁed by omission of the primary
antibodies which resulted in complete absence of immu-
nopositive structures.
Evaluation of the distribution of axonal aggregates
The severity of the axonal ataxin-3 pathology was assessed
in select tissue sections. If a given tract bore an axonal
inclusion at least once in all sections investigated in one
patient, the ﬁber tract’s axonal pathology was scored as
mild for this patient (score: 1). If it contained single
aggregates in the majority of the investigated sections or 3
or more aggregates in a single section of a given patient,
axonal pathology was rated as moderate (score: 2). If a
tract displayed 3 or more aggregates in more than half of
all sections of one patient, axonal pathology was rated as
severe (score: 3).
Statistics
SPSSversion16.0wasusedforstatisticalanalysis.Bivariate
correlations between patient data and morphological ﬁnd-
ings were evaluated using Spearman’s Rho.Two-tailedtests
were performed and considered signiﬁcant at p\0.05.
Results
In contrast to the control individuals, the combined appli-
cation of the tau-antibody AT270 [15], as axonal marker,
and the rabbit anti-ataxin-3 antibody [29], as a marker of
ataxin-3 protein aggregation, revealed intensively labeled
intra-axonal inclusion bodies in all seven SCA3 patients
(Fig. 1; Table 3).
Except for the external and extreme capsules and the
hippocampal alveus, all of the evaluated brain ﬁber tracts
were at least mildly affected by these axonal inclusions
(Table 3). Among the most severely affected ﬁber tracts
were the medial longitudinal fascicle, and the rubrospinal
and nigrostriatal tracts. Additional consistently affected
ﬁber tracts included the cranial nerves (oculomotor, tri-
geminal, facial, vagal and hypoglossal nerves), the cuneate
and gracile fascicles, the lateral lemniscus, the central
tegmental tract, the internal arcuate ﬁbers, the dorsal spi-
nocerebellar tract, the lenticular ansa and the inferior
thalamic peduncle (Figs. 1, 2, 3, 4, 5, 6; Table 3).
Most axonal aggregates were irregular in shape (Fig. 1e,
g), some were ovoid (Fig. 1a–d), or elongated and displayed
a neuritic-like shape (Fig. 1f, h). The size of axonal
aggregates varied from approximately the diameter of the
corresponding axon (Fig. 1b) to a size substantially larger
than the normal axonal diameter (Fig. 1c, d, g). These larger
aggregates were often accompanied by a comparative
thickening of the corresponding axon (Fig. 1c, g). Some-
times thinning of the tau staining within the affected axon,
proximal to the aggregations was visible, which indicates a
dilation of the axonal structure (Fig. 1c). Ataxin-3 immu-
nopositive axonal aggregates could be observed in all
portions of the affected axons (i.e. axon hillock, proximal,
middle and distal portions of the axon) (Fig. 2b). Several of
the affected axons displayed numerous abnormal aggre-
gates (Figs. 1d, f, 2a, d). Double immunostainings with the
1H9 or anti-p62 antibodies as aggregate markers and the
anti-neuroﬁlament or AT270 antibodies as an axonal
markers yielded identical staining results (Fig. 3a–d). A few
TDP-43 positive axonal inclusions were also observed (data
not shown).
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123Combined immunostaining with anti-ataxin-3 antibody
and anti-tryptophan hydroxylase PH8 [17] or anti-tyrosine
hydroxylase [4] antibodies demonstrated the axonal local-
ization of ataxin-3 immunopositive aggregates in nerve
cells of the serotonergic raphe nuclei (Fig. 2a, b), in
dopaminergic nigral neurons (Fig. 2c), and in noradrener-
gic nerve cells of the locus coeruleus (Fig. 2d). Additional
double immunostainings conﬁrmed the presence of
expanded polyglutamine stretches in the axonal protein
aggregates (Fig. 4), demonstrated their ubiquitination [10]
(Fig. 5) and immunopositivity for the shuttle protein p62
[22] (Figs. 3a, b, 6a–f). These staining results were highly
similar to those with the anti-ataxin-3/AT270 double
staining. Finally, the axonal inclusions in all of the SCA3
patients were immunonegative for abnormal tau and alpha-
synuclein protein aggregations (data not shown), and did
not demonstrate signiﬁcant accumulations of neuroﬁlament
(Fig. 4).
Statistical analysis revealed a signiﬁcant negative cor-
relation between the axonal scores of the SCA3 patients
and the length of the CAG-repeat in the mutated SCA3
gene (Spearman’s Rho -0.793, p = 0.033).
Fig. 1 Double
immunostainings with anti-
ataxin-3 and the axonal marker
AT270 showing axonal
aggregates (arrows) in the
pyramidal tract (a), oculomotor
nerve (b), facial nerve (c, d),
hypoglossal nerve (e–g) and
nigrostriatal tract (h)o f
representative SCA3 patients.
Axonal aggregates can vary in
regards to morphology between
ovoid (a–d), elongated (h)o r
irregular (e, g). Size is also
variable, from small (e)t o
several times the axonal
diameter (c, d, g). Note the
pallor of the tau staining,
indicating axonal dilation
(arrowhead)( c), and the
comparatively large axonal
diameter compared to the
unaffected neighboring axons
(arrowheads)( g). Eccentric
placement of inclusions in the
axon is rarely observable
(arrow)( e). (a–h Anti-ataxin-3
immunostaining with DAB—
brown, AT270 stain with
SK4700—blue-gray, 100 lm
PEG sections)
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123Discussion
Aggregation of the mutant disease protein is well known
in polyglutamine diseases [21, 26, 40, 45]. In SCA3,
mutant ataxin-3 tends to aggregate into NNIs with many
affected neurons exhibiting more than one inclusion body,
both in and outside of areas affected with neurodegener-
ation [29, 33, 35, 38]. While the exact role of these
aggregates in the pathological mechanisms of SCA3 is
still subject to research, they represent an acknowledged
pathological hallmark of this disease. NNIs can be rec-
ognized by both ataxin-3 speciﬁc antibodies as well as the
anti-polyglutamine 1C2 antibody, implicating mutant
ataxin-3 as the main component of NNI [49]. Further-
more, a variety of additional proteins are found to be
associated with NNI (e.g. ubiquitin, p62, heat shock
proteins, transcription factors) [18, 26, 29, 30, 38, 51].
Since polyubiquitination is a known prerequisite for pro-
teasomal degradation and the shuttle protein p62 plays a
crucial role in cellular pathways handling aberrant protein
aggregation (e.g. ubiquitin–proteasome pathway, autoph-
agy), the immunostaining of aggregates with antibodies
against ubiquitin and p62 most likely reﬂects attempts by
affected neurons to target the misfolded ataxin-3 into the
Table 3 Distribution and
severity of axonal pathology in
SCA3 patients
Investigated brain ﬁber tract,
rating of axonal ataxin-3
pathology sorted by increasing
severity (none: 0; slight: 1–5;
marked: 6–10; severe: 11?)
indicated by different shades of
gray (ND not determined)
Fiber tract   1  2  3  4  5  6  7  Axonal 
scores 
External capsule   0  0  0  0  0  0  0  0 
Extreme capsule   0  0  0  0  0  0  0  0 
Alveus of hippocampus   0  0  0  0  0  0  0  0 
Posterior commissure  0  0  0  0  0  1  0  1 
Optic radiation   0  0  1  0  0  0  0  1 
Acoustic radiation  0  0  1  0  0  0  0  1 
Corpus callosum  0  0  1  0  0  1  0  2 
Mamillothalamic tract  0  0  0  0  0  1  1  2 
Optic tract  1  0  1  0  0  0  0  2 
Posterior thalamic peduncle  0  1  1  0  0  0  0  2 
Abducens nerve  0  0  1  0  0  1  0  2 
Anterior thalamic peduncle  0  1  0  0  1  0  1  3 
Lateral thalamic peduncle  0  1  1  0  0  1  0  3 
Trochlear nerve    0  2  1  0  0  0  1  4 
Fornix  0  0  1  1  1  0  1  4 
Lateral vestibulospinal tract  1  0  1  0  0  1  1  4 
Inferior cerebellar peduncle  0  0  1  0  1  1  1  4 
Medial cerebellar peduncle  1  0  1  1  0  1  1  5 
Internal capsule   0  0  2  1  1  0  1  5 
Pontocerebellar fibers  1  0  1  1  0  1  1  5 
Medial vestibulospinal tract  1  1  1  0  0  1  1  5 
Trapezoid body  1  1  1  1  1  n.d.  0  5 
Acoustic striae   1  1  1  1  0  1  0  5 
Anterior commissure   0  1  1  1  0  1  1  5 
Ventral spinocerebellar tract  1  0  1  1  1  1  1  6 
Superior cerebellar peduncle  0  1  1  1  1  1  1  6 
Solitary tract  1  0  1  1  1  1  1  6 
Corticospinal tract  0  1  1  1  1  1  1  6 
Cerebral peduncle    1  0  1  2  1  2  0  7 
Medial lemniscus  0  1  1  1  1  2  1  7 
Ascending tract of Deiters  1  2  1  1  1  0  1  7 
Vestibulocochlear nerve  0  1  1  2  1  1  1  7 
Olivocerebellar fibers  1  2  1  1  0  1  1  7 
Dorsal spinocerebellar tract  1  1  1  2  1  1  1  8 
Inferior thalamic peduncle  0  2  2  0  1  2  1  8 
Oculomotor nerve   1  0  2  1  0  2  2  8 
Internal arcuate fibers   0  1  1  1  2  2  2  9 
Lenticular ansa    1  1  2  2  1  1  2  10 
Cuneate fascicle   1  1  1  2  2  1  2  10 
Central tegmental tract  1  2  2  2  1  1  1  10 
Hypoglossal nerve  0  0  2  3  1  1  3  10 
Lateral lemniscus   1  1  1  2  1  2  2  10 
Vagal nerve   0  0  3  1  1  3  2  10 
Trigeminal nerve   1  1  2  2  1  1  3  11 
Facial nerve   1  1  3  1  1  3  1  11 
Gracile fascicle   1  2  1  2  2  1  2  11 
Rubrospinal tract   2  2  2  1  2  1  2  12 
Nigrostriatal tract  2  3  2  2  1  2  1  13 
Medial longitudinal fascicle  2  2  2  3  2  1  2  14 
Axonal scores  27  37  57  45  33  47  48   
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123Fig. 2 Combined immunostainings with anti-ataxin-3 and anti-tryp-
tophan hydroxylase or anti-tyrosine hydroxylase antibodies depicting
axonal aggregates (arrows) in serotonergic nerve cells of the caudal
raphe nuclei (a, b), dopaminergic nerve cells of the substantia nigra
(c) and noradrenergic nerve cells of the locus coeruleus of a typical
SCA3 patient (d). Note the ataxin-3 immunopositive aggregate in the
axonal hillock of a neuron of the caudal raphe nuclei (arrow)( b).
(a, b Anti-ataxin-3 immunostaining with DAB—brown,P H 8i m m u n o -
staining with SK4700—blue-gray, c, d Anti-ataxin-3 immunostaining
with DAB—brown, anti-TH immunostaining with SK4700—blue-
gray, 100 lm PEG sections)
Fig. 3 Combined immunostaining with a p62 antibody and AT270 as
axonal marker, as well as double immunostaining for anti-ataxin-3 and
neuroﬁlament as axonal marker. p62 immunopositive axonal aggre-
gates (arrows) in the hypoglossal nerve (a) and in neurites within the
substantia nigra of a representative SCA3 patient (b). Ataxin-3
immunopositive axonal aggregates (arrows) in the hypoglossal nerve
ofatypicalSCA3patient(c,d).(a,bAnti-p62immunostainingstaining
with DAB—brown, AT270 staining with SK 4700—blue-gray,
c,d1H9anti-ataxin-3immunostainingwithDAB—brown,anti-neuro-
ﬁlament immunostaining with SK 4700—blue-gray, 100 lm PEG
sections)
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123aforementioned protein degradation pathways [2, 7, 10,
22, 29, 41, 42].
Although many reports have provided detailed analyses
of the distribution pattern of NNIs in SCA3 brains, the
occurrence of axonal aggregates in SCA3 has remained
unreported [28, 29, 35, 38]. We were for the ﬁrst time able
to demonstrate intra-axonal aggregations of mutant ataxin-
3 protein in SCA3 brain tissue, reminiscent of the neuritic
aggregates in Huntington’s disease [13]. These novel
ﬁndings suggest that axonal aggregates represent consistent
associated tissue changes of SCA3 present in a large
number of brain ﬁber tracts. SCA3 thus becomes the ﬁrst
spinocerebellar ataxia to be associated with axonal
aggregates.
The axonal inclusions detected in the present SCA3
study do not colocalize with and occur independently from
neuronal aggregates of other human proteinopathies (e.g.
tauopathies, synucleinopathies) and share major biological
hallmarks with the long-known NNIs. They can be visu-
alized with antibodies directed against ataxin-3, as well as
with the 1C2 polyglutamine antibody, indicating that
mutant ataxin-3 with its extended polyglutamine stretch
likewise represents a primary component of these axonal
aggregates [49]. Ataxin-3/ubiquitin or ataxin-3/p62 double
immunoreactions conﬁrmed their similar state of ubiquiti-
nation and association with the shuttle protein p62 as has
been observed in NNIs, indicating comparable attempts by
affected nerve cells to combat intra-axonal aggregation [2,
7, 10, 41]. Only a few axonal inclusions were also TDP-43
immunopositive, indicating that TDP-43 immunopositivity
is restricted only to a subset of axonal inclusions. Dem-
onstration of the intra-axonal localization of these axonal
aggregates is facilitated by the application of axonal
markers (i.e. AT270 and anti-neuroﬁlament antibodies)
[15, 43], as well as whole cell markers for serotonergic,
dopaminergic and noradrenergic nerve cells (i.e. PH8 and
anti-TH antibodies) [4, 17].
Axonal inclusions were present in a large variety of ﬁber
tracts of the SCA3 brains studied, irrespective of the cali-
ber or length of the affected axons. They occurred
predominantly in the ﬁber tracts that belong to the func-
tional and neurotransmitter systems known to undergo
neurodegeneration in the progressive neuropathology of
SCA3 [9, 19, 31–37]. The affected ﬁber tracts serve as
Fig. 4 1C2 and anti-
neuroﬁlament double
immunoﬂuorescence. The
oculomotor nerve (a, d)o fa
representative SCA3 patient
shows 1C2 immunopositive
aggregates indicating that
ataxin-3 with an expanded
polyglutamine stretch is a
component of these aggregates
(b, c, e, f). The low staining
intensity of neuroﬁlament
indicates that these aggregates
occur independently of age
related neuroﬁlament
aggregation (a, d). (a–f Anti-
neuroﬁlament immunostaining
with alexa 488—green, 1C2
immonostaining with Alexa
594—red,1 0lm parafﬁn
sections)
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123anatomical interconnections between gray components,
which have been shown to be selectively, consistently and
severely affected by neurodegeneration (e.g. cerebellar
dentate nucleus, primary motor cortex, sensory and motor
thalamic nuclei, substantia nigra, precerebellar nuclei,
ingestion-related brainstem nuclei, vestibular nuclei, audi-
tory and oculomotor nuclei, somatosensory nuclei) in
patients in the advanced clinical stages of SCA3, including
several of the patients investigated in the present study [19,
31–37]. In view of the close correlation of the occurrence
of intra-axonal aggregates with the consistent demise of
nerve cells in the afferent sources and/or efferent targets of
these affected ﬁber tracts it is conceivable that the forma-
tion of axonal aggregates, irrespective of their primarily
toxic or protective role, is incompatible with and detri-
mental to normal functions inside these anatomical
interconnectivities (e.g. anterograde or retrograde axonal
transport processes), thus ultimately impeding the survival
of interconnected nerve cells [16] and representing an
integral component of and important step in the neurode-
generative process of SCA3. Since it allows several
interpretations, the inverse correlation between the axonal
pathology and CAG-repeat length unfortunately does not
reveal unequivocal answers regarding an immediate detri-
mental or protective role of the intra-axonal inclusions.
Longer CAG-repeats are commonly associated with more
severe neurodegeneration [11, 20, 24, 27, 39, 45].
Assuming that intra-axonal aggregates are primarily detri-
mental to nerve cells, this inverse correlation may be due to
a greater ﬁbre loss in more severely affected SCA3 patients
[11, 35]. Since protein aggregation might also be primarily
protective against soluble and harmful oligomers of the
disease proteins [24, 46], the lower frequency of axonal
aggregates in more severely diseased SCA3 patients, on the
other hand, may reﬂect a less efﬁcient protein handling in
these patients.
In view of the current uncertainties regarding the patho-
genic mechanisms of the neurodegenerative process of
SCA3 and the possible signiﬁcance of the newly described
intra-axonal aggregates for the demise of affected and
interconnected nerve cells, it appears worthwhile to perform
additional studies aimed to test the hypothesis proposed
above and to identify the exact pathophysiological causes
and consequences of the intra-axonal aggregates in SCA3.
Fig. 5 Anti-ataxin-3 and anti-
ubiquitin double
immunoﬂuorescence. Ataxin-3
immunopositive axonal
aggregate in the
vestibulocochlear nerve of a
representative SCA3 patient
(a–c). The colocalization of
ubiquitin (red) and ataxin-3
(green) indicates
polyubiquitination of this
axonal aggregate (a–c).
Reversed staining pattern of
axonal aggregates in the
nigrostriatal tract of an
additional SCA3 patient (d–f).
These aggregates, likewise,
show colocalization of ubiquitin
(green) and ataxin-3 (red)( d–f).
(a–c Anti-ataxin-3
immunostaining with Alexa
488—green, Anti-ubiquitin
stain with Alexa 568—red, d–
f anti-ataxin-3 immunostaining
with Alexa 568—red, Anti-
ubiquitin stain with Alexa
488—green, 100 lm PEG
sections)
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123Thesestudiesshouldinclude(1)reconstructionofthespatial
and temporal evolution of these axonal aggregates and their
relationship to neurodegeneration, (2) investigation of axo-
nal accumulation of cellular organelles and proteins
involved in axonal transport mechanisms, (3) systematic
investigation of animal models of SCA3 with different dis-
ease durations [52], and will contribute to a better
understanding of the pathophysiological mechanisms of the
neurodegenerative process of SCA3.
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